289 related articles for article (PubMed ID: 26267065)
1. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
[TBL] [Abstract][Full Text] [Related]
2. CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Jääskeläinen P; Kivelä K; Laine M; Lauerma K; Kuusisto J
Sci Rep; 2019 Apr; 9(1):5960. PubMed ID: 30976029
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.
Tarkiainen M; Sipola P; Jalanko M; Heliö T; Laine M; Järvinen V; Häyrinen K; Lauerma K; Kuusisto J
J Cardiovasc Magn Reson; 2016 Jun; 18(1):33. PubMed ID: 27259862
[TBL] [Abstract][Full Text] [Related]
4. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
[TBL] [Abstract][Full Text] [Related]
5. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population.
Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Nieminen MS; Laakso M; Kuusisto J; ; Kervinen H; Mustonen J; Juvonen J; Niemi M; Uusimaa P; Huttunen M; Kotila M; Pietilä M
Ann Med; 2013 Feb; 45(1):85-90. PubMed ID: 22462493
[TBL] [Abstract][Full Text] [Related]
6. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
7. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy.
Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Kärkkäinen S; Peuhkurinen K; Nieminen MS; Laakso M; ; Kuusisto J
Ann Med; 2014 Sep; 46(6):424-9. PubMed ID: 24888384
[TBL] [Abstract][Full Text] [Related]
8. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
[TBL] [Abstract][Full Text] [Related]
9. A novel cardiac myosin-binding protein C S297X mutation in hypertrophic cardiomyopathy.
Hirota T; Kubo T; Kitaoka H; Hamada T; Baba Y; Hayato K; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Doi YL
J Cardiol; 2010 Jul; 56(1):59-65. PubMed ID: 20350521
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
[TBL] [Abstract][Full Text] [Related]
11. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
[TBL] [Abstract][Full Text] [Related]
13. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.
Konno T; Shimizu M; Ino H; Fujino N; Uchiyama K; Mabuchi T; Sakata K; Kaneda T; Fujita T; Masuta E; Mabuchi H
Clin Sci (Lond); 2006 Jan; 110(1):125-31. PubMed ID: 16181148
[TBL] [Abstract][Full Text] [Related]
15. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
16. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
[TBL] [Abstract][Full Text] [Related]
17. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.
Timmer SA; Germans T; Brouwer WP; Lubberink M; van der Velden J; Wilde AA; Christiaans I; Lammertsma AA; Knaapen P; van Rossum AC
Eur J Heart Fail; 2011 Dec; 13(12):1283-9. PubMed ID: 22021246
[TBL] [Abstract][Full Text] [Related]
18. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations.
Jalanko M; Heliö T; Mustonen P; Kokkonen J; Huhtala H; Laine M; Jääskeläinen P; Tarkiainen M; Lauerma K; Sipola P; Laakso M; Kuusisto J; Nikus K
J Electrocardiol; 2018; 51(6):983-989. PubMed ID: 30497761
[TBL] [Abstract][Full Text] [Related]
19. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
[TBL] [Abstract][Full Text] [Related]
20. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
